Erick Guerrero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Erick Guerrero has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Daniel John Siegwart
Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA
5 shared publications - Lukas Farbiak
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, University of Texas Southwestern Medical Center, Dallas, USA
3 shared publications - Xu Wang
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, University of Texas Southwestern Medical Center, Dallas, USA
3 shared publications - Amogh Vaidya
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications - Ankit Gupta
Center for Alzheimer’s and Neurodegenerative Diseases, Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications - Cecilia Leal
Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
2 shared publications
Latest Publications
- Open Access
- 23 August 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (59) , e74762
Esterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration
The blood–brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating molecular and cellular exchange between the brain and peripheral circulation. While most delivery strategies focus on crossing the BBB, targeting brain endothelial cells directly may offer a complementary and more controlled alternative for therapeutic intervention. This study presents a ligand‐free lipid nanoparticle (LNP) platform that enables efficient mRNA delivery to the brain endothelium via systemic administration. A modular synthesis strategy was used to generate a chemically diverse library of cholesterol‐based lipids. Screening of 486 LNPs identified an optimized four‐component formulation consisting of C6O2B2 (novel cholesterol‐based lipid), DODAP, DSPC, and DMG‐PEG, which achieves high transfection efficiency in brain endothelial cells without the incorporation of free cholesterol or disruption of BBB integrity and function, such as those utilized in focused ultrasound (FUS) techniques. This BBB‐targeting LNP platform avoids neuronal and glial transfection, thereby offering a noninvasive, and scalable approach for cerebrovascular gene delivery. The work establishes a new class of cholesterol‐based lipids and provides a foundation for next‐generation RNA therapeutics targeting BBB‐associated diseases.
- 23 August 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (59) , e74762
Open AccessEsterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration
The blood–brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating molecular and cellular exchange between the brain and peripheral circulation. While most delivery strategies focus on crossing the BBB, targeting brain endothelial cells directly may offer a complementary and more controlled alternative for therapeutic intervention. This study presents a ligand‐free lipid nanoparticle (LNP) platform that enables efficient mRNA delivery to the brain endothelium via systemic administration. A modular synthesis strategy was used to generate a chemically diverse library of cholesterol‐based lipids. Screening of 486 LNPs identified an optimized four‐component formulation consisting of C6O2B2 (novel cholesterol‐based lipid), DODAP, DSPC, and DMG‐PEG, which achieves high transfection efficiency in brain endothelial cells without the incorporation of free cholesterol or disruption of BBB integrity and function, such as those utilized in focused ultrasound (FUS) techniques. This BBB‐targeting LNP platform avoids neuronal and glial transfection, thereby offering a noninvasive, and scalable approach for cerebrovascular gene delivery. The work establishes a new class of cholesterol‐based lipids and provides a foundation for next‐generation RNA therapeutics targeting BBB‐associated diseases.
- 30 August 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123671
Investigating the functional contributions of phospholipids in selective organ targeting lipid nanoparticles
- 30 August 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123671
Investigating the functional contributions of phospholipids in selective organ targeting lipid nanoparticles
- Open Access
- 4 June 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (8) , 1320
Publisher Correction: High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
- 4 June 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (8) , 1320
Open AccessPublisher Correction: High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
- Top Cited Papers
- 28 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (11) , 1840-1851
High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
Messenger RNA lipid-nanoparticle-based therapies represent an emerging class of medicines for a variety of applications. However, anti-poly(ethylene glycol) (anti-PEG) antibodies generated by widely used PEGylated medicines and lipid nanoparticles hinder therapeutic efficacy upon repeated dosing. Here we report the chemical design, synthesis and optimization of high-density brush-shaped polymer lipids that reduce anti-PEG antibody binding to improve protein production consistency in repeated dosing. Brush-shaped polymer lipid parameters, including side chain length, degree of polymerization, anchor alkyl length and surface regimes on lipid nanoparticles modulate anti-PEG antibody binding affinity and control their blood circulation pharmacokinetics. Compared to widely used 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, lipid nanoparticles containing brush-shaped polymer lipids generate superior therapeutic outcomes in protein replacement therapy and genome editing models, reformulating structure–activity guidelines for the design of PEG lipid substitutes. Overall, these findings contribute to the general effort in the development of lipid nanoparticles with low immunogenicity to overcome current roadblocks to nucleic acid medicines.
- 28 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (11) , 1840-1851
Top Cited PapersHigh-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
Messenger RNA lipid-nanoparticle-based therapies represent an emerging class of medicines for a variety of applications. However, anti-poly(ethylene glycol) (anti-PEG) antibodies generated by widely used PEGylated medicines and lipid nanoparticles hinder therapeutic efficacy upon repeated dosing. Here we report the chemical design, synthesis and optimization of high-density brush-shaped polymer lipids that reduce anti-PEG antibody binding to improve protein production consistency in repeated dosing. Brush-shaped polymer lipid parameters, including side chain length, degree of polymerization, anchor alkyl length and surface regimes on lipid nanoparticles modulate anti-PEG antibody binding affinity and control their blood circulation pharmacokinetics. Compared to widely used 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, lipid nanoparticles containing brush-shaped polymer lipids generate superior therapeutic outcomes in protein replacement therapy and genome editing models, reformulating structure–activity guidelines for the design of PEG lipid substitutes. Overall, these findings contribute to the general effort in the development of lipid nanoparticles with low immunogenicity to overcome current roadblocks to nucleic acid medicines.
- Top Cited Papers
- 18 January 2022
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 10 (2) , 549-559
Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA)
Lipid nanoparticles (LNPs) have been established as an essential platform for nucleic acid delivery. Efforts have led to the development of vaccines that protect against SARS-CoV-2 infection using LNPs to deliver messenger RNA (mRNA) coding for the viral spike protein. Out of the four essential components that comprise LNPs, phospholipids represent an underappreciated opportunity for fundamental and translational study. We investigated this avenue by systematically modulating the identity of the phospholipid in LNPs with the goal of identifying specific moieties that directly enhance or hinder delivery efficacy. Results indicate that phospholipid chemistry can enhance mRNA delivery by increasing membrane fusion and enhancing endosomal escape. Phospholipids containing phosphoethanolamine (PE) head groups likely increase endosomal escape due to their fusogenic properties. Additionally, it was found that zwitterionic phospholipids mainly aided liver delivery, whereas negatively charged phospholipids changed the tropism of the LNPs from liver to spleen. These results demonstrate that the choice of phospholipid plays a role intracellularly by enhancing endosomal escape, while also driving organ tropism in vivo. These findings were then applied to Selective Organ Targeting (SORT) LNPs to manipulate and control spleen-specific delivery. Overall, selection of the phospholipid in LNPs provides an important handle to design and optimize LNPs for improved mRNA delivery and more effective therapeutics.
- 18 January 2022
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 10 (2) , 549-559
Top Cited PapersOptimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA)
Lipid nanoparticles (LNPs) have been established as an essential platform for nucleic acid delivery. Efforts have led to the development of vaccines that protect against SARS-CoV-2 infection using LNPs to deliver messenger RNA (mRNA) coding for the viral spike protein. Out of the four essential components that comprise LNPs, phospholipids represent an underappreciated opportunity for fundamental and translational study. We investigated this avenue by systematically modulating the identity of the phospholipid in LNPs with the goal of identifying specific moieties that directly enhance or hinder delivery efficacy. Results indicate that phospholipid chemistry can enhance mRNA delivery by increasing membrane fusion and enhancing endosomal escape. Phospholipids containing phosphoethanolamine (PE) head groups likely increase endosomal escape due to their fusogenic properties. Additionally, it was found that zwitterionic phospholipids mainly aided liver delivery, whereas negatively charged phospholipids changed the tropism of the LNPs from liver to spleen. These results demonstrate that the choice of phospholipid plays a role intracellularly by enhancing endosomal escape, while also driving organ tropism in vivo. These findings were then applied to Selective Organ Targeting (SORT) LNPs to manipulate and control spleen-specific delivery. Overall, selection of the phospholipid in LNPs provides an important handle to design and optimize LNPs for improved mRNA delivery and more effective therapeutics.
- 4 March 2021
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 4 (3) , 2423-2433
Carbon Quantum Dots for Treatment of Amyloid Disorders
Prion-like amyloids self-template and form toxic oligomers, protofibrils, and fibrils from their soluble monomers; a phenomenon that has been implicated in the onset and progress of neurodegenerative disorders such as Alzheimer’s (AD), Parkinson’s (PD), Huntington’s, and systemic lysozyme amyloidosis. Carbon quantum dots (CQDs), sourced from Na–citrate as a carbon precursor were synthesized and characterized before being tested for their ability to intervene in amyloidogenic (fibril-forming) trajectories. Hen-egg white lysozyme (HEWL) served as a model amyloidogenic protein. A pulse-chase lysozyme fibril-forming assay developed to examine the impact of CQDs on the HEWL amyloid-fibril-forming trajectory used ThT fluorescence as a reporter of mature fibril presence. The results revealed that the Na–citrate-derived CQDs were able to intervene at multiple points along the fibril-forming trajectory by preventing the conversion of both monomeric and oligomeric HEWL intermediates into mature fibrils. In addition, and importantly, the carbon nano material (CNM) was able to dissolve oligomeric HEWL into monomeric HEWL and provoke the disaggregation of mature HEWL fibrils. These results suggest that Na–citrate CQD’s intervene in amyloidogenesis by multiple mechanisms. The gathered data, coupled with cell-line results demonstrating the relatively low cytotoxicity of Na–citrate CQDs, suggest that this emerging CNM has the potential to intervene both prophylactically and therapeutically in protein misfolding diseases. The aforementioned findings are likely to enable Na–citrate CQDs to eventually transition to both cell-line and preclinical models of protein-misfolding-related disorders. Importantly, the study outcomes positions Na–citrate CQDs as an important class of chemical, nanotechnological, and biobased interventional tools in neuroscience.
- 4 March 2021
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 4 (3) , 2423-2433
Carbon Quantum Dots for Treatment of Amyloid Disorders
Prion-like amyloids self-template and form toxic oligomers, protofibrils, and fibrils from their soluble monomers; a phenomenon that has been implicated in the onset and progress of neurodegenerative disorders such as Alzheimer’s (AD), Parkinson’s (PD), Huntington’s, and systemic lysozyme amyloidosis. Carbon quantum dots (CQDs), sourced from Na–citrate as a carbon precursor were synthesized and characterized before being tested for their ability to intervene in amyloidogenic (fibril-forming) trajectories. Hen-egg white lysozyme (HEWL) served as a model amyloidogenic protein. A pulse-chase lysozyme fibril-forming assay developed to examine the impact of CQDs on the HEWL amyloid-fibril-forming trajectory used ThT fluorescence as a reporter of mature fibril presence. The results revealed that the Na–citrate-derived CQDs were able to intervene at multiple points along the fibril-forming trajectory by preventing the conversion of both monomeric and oligomeric HEWL intermediates into mature fibrils. In addition, and importantly, the carbon nano material (CNM) was able to dissolve oligomeric HEWL into monomeric HEWL and provoke the disaggregation of mature HEWL fibrils. These results suggest that Na–citrate CQD’s intervene in amyloidogenesis by multiple mechanisms. The gathered data, coupled with cell-line results demonstrating the relatively low cytotoxicity of Na–citrate CQDs, suggest that this emerging CNM has the potential to intervene both prophylactically and therapeutically in protein misfolding diseases. The aforementioned findings are likely to enable Na–citrate CQDs to eventually transition to both cell-line and preclinical models of protein-misfolding-related disorders. Importantly, the study outcomes positions Na–citrate CQDs as an important class of chemical, nanotechnological, and biobased interventional tools in neuroscience.